iRhythm stock price target lowered to $150 by Wells Fargo on model update
Wells Fargo lowered its price target on iRhythm Technologies (IRTC) to $150 from $168, citing updated models post-VitalPatch acquisition. IRTC trades at $109.09 with a $3.6B market cap. Analysts expect 62% upside. Q2 revenue was $224.2M, beating estimates. IRTC raised 2026 revenue guidance, targeting 15% adjusted EBITDA margin by 2027.
How this was made
The 30-second read
Why it matters
The target reduction and margin revisions signal a near‑term downside, but the acquisition could unlock longer‑term upside.
Market read
Analyst target cut and acquisition details provide fresh actionable insight for IRTC traders.
What to watch
Potential synergies from VitalPatch could improve future margins beyond current analyst assumptions.
Background
Wells Fargo updated its valuation model after the VitalPatch acquisition closed earlier than expected, adjusting sales and margin forecasts.
Ticker impact
Wells Fargo lowered IRTC price target to $150 and noted the VitalPatch acquisition, providing fresh analyst guidance.
likely pressure as the market prices in the lower target and margin revisions
Analyst downgrade with a concrete new target and margin assumptions typically moves the stock in the direction of the downgrade.
Market effects
The downgrade may weigh on other digital health and remote monitoring stocks as valuation assumptions are revisited.
Limited to U.S. listed health‑tech equities.
Minimal beyond the niche sector.
Counterpoint
Some investors may view the acquisition as a long‑term growth catalyst despite the short‑term target cut.
Key entities
- companyiRhythm Technologies
Provider of cardiac monitoring solutions, ticker IRTC.
- companyVitalPatch
Acquired digital health firm integrated into iRhythm.
